InnoCare Gains Approval for ICP-B794 Clinical Trial in China

BEIJING, China I July 03, 2025 I InnoCare Pharma, a prominent biopharmaceutical firm listed on HKEX and SSE, has announced a significant milestone in its ongoing research efforts. The company has received approval from the Center for Drug Evaluation of the China National Medical Products Administration to initiate clinical trials for a novel antibody-drug conjugate (ADC), ICP-B794, targeting B7-H3.

ICP-B794 represents an innovative approach to cancer treatment. It consists of a humanized monoclonal antibody targeting B7-H3, linked to a powerful payload through a protease-cleavable linker. This design ensures that the drug specifically targets tumor cells, thereby significantly reducing potential side effects. ICP-B794 shows promise in treating various solid tumors, including those affecting the lungs, esophagus, nasopharynx, head and neck, and prostate.

Currently, there are no B7-H3 targeted therapies available on the global market. B7-H3, a type I transmembrane protein, is notably expressed in many solid tumors, making it a valuable target for cancer treatment. Its specific expression in tumor cells highlights its potential as an effective anti-cancer target.

Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, remarked on the development, stating that ICP-B794 is a product of the company's proprietary ADC platform. This platform is engineered to deliver ADCs with high efficacy in tumor destruction and a favorable therapeutic window. The platform's continued development promises a broader range of treatment options for cancer patients, potentially improving their clinical outcomes. InnoCare aims to expand its portfolio with differentiated ADC candidates as the platform evolves, thereby advancing precision medicine in oncology.

InnoCare is dedicated to addressing the growing demands in the treatment of solid tumors. The company is focused on developing a competitive portfolio of drugs targeting a wide range of solid tumor indications. By integrating targeted therapies, immune-oncology strategies, and advanced ADC technology, InnoCare is expanding its research and development pipeline. The R&D efforts are concentrated on novel platforms targeting various solid tumors, using innovative technologies to identify promising drug candidates that offer substantial clinical benefits. InnoCare's proprietary ADC technology, alongside potential precision medicine candidates like the TRK inhibitor zurletrectinib (ICP-723), positions the company to strengthen its role in solid tumor treatment.

InnoCare is a commercial-stage biopharmaceutical company engaged in discovering, developing, and bringing to market first-in-class or best-in-class drugs for treating cancers and autoimmune diseases with unmet medical needs, both in China and internationally. The company has a presence in multiple locations, including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.